Rule 3.19A.2

# **Appendix 3Y**

### **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OSPREY MEDICAL INC.	
ABN	ARBN 152 854 923	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Erb
Date of last notice	22 May 2017

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Cancellation of 20,000 Options (unquoted) to subscribe for shares of common stock of the Company (unquoted) (Shares)		
Date of change	11 October 2017 (AEST)		
No. of securities held prior to change	20,000 Options with exercise price of US\$0.50 per Share		
	5,000 Options with exercise price of US\$0.50 per Share		
	73,839 Options with exercise price of US\$0.25 per Share		
	190,000 Options with exercise price of US\$0.80 per Share		
	100,000 Options with exercise price of A\$1.31 per Share		
	60,000 Options with exercise price of A\$1.16 per Share		
	110,000* Options with exercise price of A\$0.82 per Share		
	Total: 558,839 Options (exercisable into an equivalent of 1,117,678 CDIs)		

<sup>+</sup> See chapter 19 for defined terms.

Class	Options over Shares (not quoted)		
Number cancelled	20,000 Options (equivalent to 40,000 CDIs)		
Number disposed	Nil		
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Nil		
No. of securities held after change			
	5,000 Options with exercise price of US\$0.50 per Share		
	73,839 Options with exercise price of US\$0.25 per Share		
	190,000 Options with exercise price of US\$0.80 per Share		
	100,000 Options with exercise price of A\$1.31 per Share		
	60,000 Options with exercise price of A\$1.16 per Share		
	110,000 Options with exercise price of A\$0.82 per Share		
	Total: 538,839 Options (exercisable into an equivalent of 1,077,678 CDIs)		
Nature of change	Cancellation of Options with an exercise price of		
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	US\$0.50 per share previously issued to John Erb in 2007.		

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – <sup>+</sup>Closed period

Were the interests in the securities or contracts	No
detailed above traded during a <sup>+</sup> closed period	
where prior written clearance was required?	
If so, was prior written clearance provided to allow	N/A
the trade to proceed during this period?	
If prior written clearance was provided, on what	N/A
date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.